U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H11IN2O4
Molecular Weight 338.0991
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROPIDOXURIDINE

SMILES

OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(I)C=NC2=O

InChI

InChIKey=XIJXHOVKJAXCGJ-XLPZGREQSA-N
InChI=1S/C9H11IN2O4/c10-5-2-11-9(15)12(3-5)8-1-6(14)7(4-13)16-8/h2-3,6-8,13-14H,1,4H2/t6-,7+,8+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm; http://www.ncbi.nlm.nih.gov/pubmed/9336833; http://www.ncbi.nlm.nih.gov/pubmed/12705773; http://www.ncbi.nlm.nih.gov/pubmed/14435162; http://www.ncbi.nlm.nih.gov/pubmed/4309419

Ropidoxuridine is a thymidine analogue and an oral prodrug of iododeoxyuridine that is easier to administer and less toxic with a more favorable therapeutic index in preclinical studies. Iododeoxyuridine demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor. Ropidoxuridine may help radiation therapy work better by making tumor cells more sensitive to the radiation therapy. In 2019, phase I clinical trials were ongoing to study the best dose of ropidoxuridine and its side effects in patients with metastatic malignant neoplasm in the brain and in patients with metastatic gastrointestinal cancer. First results showed that ropidoxuridine, combined with radiation therapy, was well-tolerated in patients with metastatic gastrointestinal cancer.

CNS Activity

Curator's Comment: In rat brain

Originator

Curator's Comment: Late 1950s

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2366042
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DENDRID

Approved Use

For the treatment of keratitis caused by the virus of herpes simplex.

Launch Date

1963
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
139.03 μM × h
4538 mg/m² 1 times / day multiple, intraperitoneal
dose: 4538 mg/m²
route of administration: Intraperitoneal
experiment type: MULTIPLE
co-administered:
IDOXURIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus.
1976 Mar
HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors.
2002 Dec 1
Metallocene-DNA: synthesis, molecular and electronic structure and DNA incorporation of C5-ferrocenylthymidine derivatives.
2002 Jul 2
Modelling the effect of incorporated halogenated pyrimidine on radiation-induced DNA strand breaks.
2002 Nov
Interventions for herpes simplex virus epithelial keratitis.
2003
Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy.
2003 Aug
Exploration of the influence of 5-iodo-2'-deoxyuridine incorporation on the structure of d[CACG(IDU)G].
2003 Aug
Efficient one-step Suzuki arylation of unprotected halonucleosides, using water-soluble palladium catalysts.
2003 Aug 22
Comparative study of purine and pyrimidine nucleoside analogues acting on the thymidylate kinases of Mycobacterium tuberculosis and of humans.
2003 Aug 4
Postherpetic neuralgia.
2003 Dec
Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
2003 Dec
[Anti-herpetic chemotherapeutic drugs].
2003 Feb
A balanced deoxyribonucleoside mixture increased the rate of DNA incorporation of 5-[125I]Iodo-2'-deoxyuridine in glioblastoma cells.
2003 Feb
Novel agents and strategies to treat herpes simplex virus infections.
2003 Feb
Preclinical Auger and gamma radiation dosimetry for fluorodeoxyuridine-enhanced tumour proliferation scintigraphy with [123I]iododeoxyuridine.
2003 Feb
Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents.
2003 Feb
Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas.
2003 Feb 1
Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization.
2003 Feb 15
In vitro activity of potential anti-poxvirus agents.
2003 Jan
Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent.
2003 Jul
Postherpetic neuralgia.
2003 Jun
Randomized, open-labelled comparison between an idoxuridine 10% gel and acyclovir 5% cream in recurrent herpes labialis.
2003 Mar
Clinical significance of atomic inner shell ionization (ISI) and Auger cascade for radiosensitization using IUdR, BUdR, platinum salts, or gadolinium porphyrin compounds.
2003 Mar 15
Functional expression of a sodium dependent nucleoside transporter on rabbit cornea: Role in corneal permeation of acyclovir and idoxuridine.
2003 Mar-Apr
A simple and efficient method for synthesis of 5-substituted 2'-deoxyuridine nucleosides using metal-halogen exchange reaction of 5-iodo-2'-deoxyuridine sodium salt.
2003 May 7
Design of Mycobacterium tuberculosis thymidine monophosphate kinase inhibitors.
2003 May-Aug
Biliary obstruction reduces hepatic killing and phagocytic clearance of circulating microorganisms in rats.
2003 May-Jun
Use of radiolabelled iododeoxyuridine as adjuvant treatment for experimental tumours of the liver.
2003 Oct
Role of MutSalpha in the recognition of iododeoxyuridine in DNA.
2003 Sep 1
Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides.
2004
In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1.
2004 Apr
Tracers to monitor the response to chemotherapy: in vitro screening of four radiopharmaceuticals.
2004 Aug
New tertiary constraints between the RNA components of active yeast spliceosomes: a photo-crosslinking study.
2004 Aug
Synchrotron radiation-based experimental determination of the optimal energy for cell radiotoxicity enhancement following photoelectric effect on stable iodinated compounds.
2004 Aug 2
Effects of single-pulse (< or = 1 ps) X-rays from laser-produced plasmas on mammalian cells.
2004 Dec
Neural stem cell detection, characterization, and age-related changes in the subventricular zone of mice.
2004 Feb 18
Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus.
2004 Jan
Positive interactive radiosensitisation in vitro with the combination of two nucleoside analogues, (E)-2'-deoxy-2'-(fluoromethylene) cytidine and iododeoxyuridine.
2004 Jul
Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
2004 Jul 15
Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model.
2004 Jul 19
Antiviral drugs in current clinical use.
2004 Jun
Feasibility of sodium/iodide symporter gene as a new imaging reporter gene: comparison with HSV1-tk.
2004 Mar
[The latest in herpes simplex keratitis therapy].
2004 May
Indian hedgehog: a mechanotransduction mediator in condylar cartilage.
2004 May
The preparation of clinical grade 5-[123I]iodo-2'-deoxyuridine and 5-[125I]iodo-2'-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphy.
2004 May
Polyphosphoinositides-dependent regulation of the osteoclast actin cytoskeleton and bone resorption.
2004 May 13
Highly efficient DNA incorporation of intratumourally injected [125I]iododeoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts.
2004 May 20
Synthesis and antiviral activities of 1'-carbon-substituted 4'-thiothymidines.
2004 Oct 15
[Therapeutic effect of 125IUdR on the glioma cell line C6 in vitro and in vivo].
2004 Sep
Overexpression of p27 Kip 1, probability of cell cycle exit, and laminar destination of neocortical neurons.
2005 Sep
Patents

Sample Use Guides

1 drop (0.1% solution) every hour
Route of Administration: Topical
In Vitro Use Guide
Antiviral susceptibility of herpes simplex viruses by idoxuridine was studied in human culture cell line WI-38. Eight concentrations were tested, beginning with 1000 ug/ml and subsequent serial one-fourth dilutions. Mean MIC was 0.5 mg/ml.
Name Type Language
ROPIDOXURIDINE
INN   USAN  
INN   USAN  
Official Name English
IPDR
Code English
ROPIDOXURIDINE [USAN]
Common Name English
2(1H)-PYRIMIDINONE, 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODO-
Common Name English
IPD-R
Code English
NSC-726188
Code English
1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODOPYRIMIDIN-2(1H)-ONE
Common Name English
ropidoxuridine [INN]
Common Name English
5-IODO-2-PYRIMIDINONE-2'-DEOXYRIBOSE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C798
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
FDA ORPHAN DRUG 519016
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
FDA ORPHAN DRUG 222606
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
NCI_THESAURUS C1557
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
FDA ORPHAN DRUG 690919
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
Code System Code Type Description
NSC
726188
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
PRIMARY
NCI_THESAURUS
C48813
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
PRIMARY
FDA UNII
3HX21A3SQF
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
PRIMARY
MESH
C045889
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
PRIMARY
PUBCHEM
9840777
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
PRIMARY
DRUG BANK
DB06485
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
PRIMARY
EPA CompTox
DTXSID00239353
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
PRIMARY
INN
8831
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
PRIMARY
USAN
SS-20
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
PRIMARY
CAS
93265-81-7
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
PRIMARY
ChEMBL
CHEMBL2103821
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
PRIMARY
SMS_ID
300000036831
Created by admin on Fri Dec 15 16:37:44 GMT 2023 , Edited by admin on Fri Dec 15 16:37:44 GMT 2023
PRIMARY